ASH 2015 highlights by Prof. Michael Hallek
Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Inherited and acquired genetic factors involved in the development of CLL
John Gribben et al.
Addressing the issue of cost of treatment in CLL
Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapy